Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization Joseph A. SparanoGabriel N. HortobagyiRobert L. Comis Editorial 14 June 2009 Pages: 511 - 527
Loco-regional treatment in metastatic breast cancer patients: Is there a survival benefit? Bevan H. LyNam P. NguyenGeorges Vlastos Review 30 October 2009 Pages: 537 - 545
The silent mutation nucleotide 744 G → A, Lys172Lys, in exon 6 of BRCA2 results in exon skipping Thomas V. O. HansenAne Y. SteffensenFinn C. Nielsen Preclinical Study 08 March 2009 Pages: 547 - 550
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer Marieke E. StraverAnnuska M. GlasSjoerd Rodenhuis Preclinical Study 13 February 2009 Pages: 551 - 558
RETRACTED ARTICLE: Glypican-3 reexpression regulates apoptosis in murine adenocarcinoma mammary cells modulating PI3K/Akt and p38MAPK signaling pathways C. BuchananI. StiglianoM. G. Peters Preclinical Study 14 March 2009 Pages: 559 - 574
Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance Nicholas B. P. ThomasIain R. HutchesonMark Gumbleton Preclinical Study 15 March 2009 Pages: 575 - 591
Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach Yijun SunVirginia UrquidiSteve Goodison Preclinical study 17 March 2009 Pages: 593 - 599
Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer De-Yuan FuZhi-Min WangZhi-Ming Shao Preclinical Study 20 March 2009 Pages: 601 - 612
Women’s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid Angela FagerlinBrian J. Zikmund-FisherPeter A. Ubel Clinical Trial 12 November 2009 Pages: 613 - 620
Fifteen-year trends in metastatic breast cancer survival in Greece U. DafniI. GrimaniG. Fountzilas Clinical trial 14 November 2009 Pages: 621 - 631
Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N·SAS-BC 01 trial and CUBC trial) Yasuo OhashiToru WatanabeTakaichiro Suzuki Clinical trial 21 November 2009 Pages: 633 - 641
A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer Fiona M. McCaigLorna RenshawJ. Michael Dixon Clinical trial 26 November 2009 Pages: 643 - 651
A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Yeon Hee ParkSeung Tae KimYoung-Hyuck Im Clinical trial 03 December 2009 Pages: 653 - 661
A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial Stacy MoulderHailun LiGeorge W. Sledge Clinical trial 10 December 2009 Pages: 663 - 671
A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study Ursula WiedermannC. WiltschkeC. C. Zielinski Clinical trial 11 December 2009 Pages: 673 - 683
Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer Larissa A. KordeLara LusaJo Anne Zujewski Clinical Trial 11 December 2009 Pages: 685 - 699
Association of interleukin-10 gene variation with breast cancer prognosis Armin GergerWilfried RennerUwe Langsenlehner Epidemiology 13 May 2009 Pages: 701 - 705
Treatment-related symptoms among underserved women with breast cancer: the impact of physician–patient communication Rose C. MalyYihang LiuAllison L. Diamant Epidemiology 16 May 2009 Pages: 707 - 716
nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial George DranitsarisRobert ColemanWilliam Gradishar Epidemiology 03 June 2009 Pages: 717 - 724
Impact of menopausal symptoms on quality of life 6 months after systemic breast cancer treatment: results from the Shanghai Breast Cancer Survival Study Tsogzolmaa DorjgochooAsha KallianpurXiao Ou Shu Epidemiology 20 June 2009 Pages: 725 - 735
Characterization of BRCA1 ring finger variants of uncertain significance Kevin SweetLeigha SenterAmanda Ewart Toland Epidemiology 20 June 2009 Pages: 737 - 743
Validity of self-reports of breast cancer treatment in low-income, medically underserved women with breast cancer Yihang LiuAllison L. DiamantRose C. Maly Epidemiology 24 June 2009 Pages: 745 - 751
Dietary β-carotene, vitamin C and E intake and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) G. NagelJ. LinseisenE. Riboli Epidemiology 30 June 2009 Pages: 753 - 765
Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy M. N. VoM. EvansA. Lipton Brief Report 30 December 2008 Pages: 767 - 771
NIP1/DUOXA1 expression in epithelial breast cancer cells: regulation of cell adhesion and actin dynamics Elena A. OstrakhovitchShawn S. C. Li Brief Report 26 March 2009 Pages: 773 - 786
